Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
6
Bullish
4
Bearish
22
Neutral
6
Bullish
18
Bearish
18
Neutral
0
Bullish
14
Discovery themes featuring this stock
IOL Chemicals and Pharmaceuticals Limited manufactures active pharmaceutical ingredients and specialty chemicals, serving pharmaceutical, industrial and consumer-facing applications globally. Its portfolio includes Ibuprofen, Metformin, Clopidogrel, Lamotrigine, Pantoprazole, Fenofibrate, Ethyl Acetate, Iso Butyl Benzene and other chemicals, supported by backward integration, manufacturing facilities in Punjab and exports to more than 80 countries.
IOLCP delivered its highest-ever quarterly revenue, EBITDA and PAT in Q2 FY27, with revenue rising 40.1% year-on-year to ₹795.0 crore, EBITDA increasing 79.6% to ₹114.9 crore and PAT more than doubling to ₹65.0 crore. EBITDA margin expanded 321 basis points to 14.4%, indicating stronger realisations, product mix and operating efficiency.
Pharmaceutical diversification is becoming materially important: non-Ibuprofen products grew approximately 70% year-on-year and represented 45% of pharmaceutical revenue in Q2 FY27, compared with 38% a year earlier. This reduces dependence on the company’s flagship Ibuprofen franchise while demonstrating stronger contribution from products across multiple therapeutic categories.
The Chemicals segment showed a sharp operational recovery, with Q2 FY27 EBIT contribution reaching approximately 7% versus 1% in the prior-year quarter. Segment revenue increased to ₹322.3 crore from ₹231.2 crore, while EBIT rose to ₹23.2 crore, supported by improved realisations and operating performance.
IOLCP is positioning its manufacturing platform for higher-value growth through forward integration into contract development and manufacturing organisation services and formulations. Management views this as a natural extension of existing process expertise, intended to broaden customer solutions, deepen relationships and improve long-term portfolio quality.
Pharmaceuticals & Biotechnology
Pharmaceuticals
5,426 Cr
Moderate Risk
32.3
37.0
0.8
3.0
224.00
67.14
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1050.70 | 6,013 Cr | 39.04 | 5.51 | 0.19 | 12.92 | 14.30 | 8.38 | ||
183.25 | 5,947 Cr | 3.75 | 4.44 | 0.00 | 116.01 | 80.89 | 72.98 | ||
1218.55 | 5,612 Cr | 40.87 | 5.60 | 0.00 | 12.36 | 14.43 | 8.16 | ||
184.85 | 5,426 Cr | 32.28 | 3.02 | 0.54 | 7.65 | 10.29 | 6.50 | ||
891.95 | 5,341 Cr | 540.09 | 3.41 | 0.00 | 1.34 | 1.62 | 0.62 | ||
2995.65 | 4,955 Cr | 44.63 | 8.18 | 0.80 | 19.03 | 24.66 | 15.08 | ||
374.85 | 4,879 Cr | 100.22 | 6.44 | 0.15 | — | — | 0.00 | ||
| Median: 7 Co. | — | 891.95 | 5,426 Cr | 40.87 | 5.51 | 0.15 | 12.64 | 14.36 | 8.16 |
Financial Results
IOL Chemicals & Pharmaceuticals reported Q2 FY27 revenue of ₹795.0 crore, EBITDA of ₹114.9 crore and PAT of ₹65.0 crore, rising 40.1%, 79.6% and 116.8% year-on-year, respectively.
Financial Results
IOL Chemicals approved standalone and consolidated unaudited financial results for the quarter and half year ended 30 September 2026, with unmodified limited review reports.
Earnings Call/Transcript
IOL Chemicals & Pharmaceuticals will hold an analyst and investor conference call on 2 November 2026 at 11:30 AM IST to discuss Q2 and H1 FY27 financial performance.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
IOL Chemicals & Pharmaceuticals Ltd (IOLCP) is currently trading at 180.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
IOL Chemicals and Pharmaceuticals Limited manufactures active pharmaceutical ingredients and specialty chemicals, serving pharmaceutical, industrial and consumer-facing applications globally. Its portfolio includes Ibuprofen, Metformin, Clopidogrel, Lamotrigine, Pantoprazole, Fenofibrate, Ethyl Acetate, Iso Butyl Benzene and other chemicals, supported by backward integration, manufacturing facilities in Punjab and exports to more than 80 countries. IOLCP delivered its highest-ever quarterly revenue, EBITDA and PAT in Q2 FY27, with revenue rising 40.1% year-on-year to ₹795.0 crore, EBITDA increasing 79.6% to ₹114.9 crore and PAT more than doubling to ₹65.0 crore. EBITDA margin expanded 321 basis points to 14.4%, indicating stronger realisations, product mix and operating efficiency. Pharmaceutical diversification is becoming materially important: non-Ibuprofen products grew approximately 70% year-on-year and represented 45% of pharmaceutical revenue in Q2 FY27, compared with 38% a year earlier. This reduces dependence on the company’s flagship Ibuprofen franchise while demonstrating stronger contribution from products across multiple therapeutic categories. The Chemicals segment showed a sharp operational recovery, with Q2 FY27 EBIT contribution reaching approximately 7% versus 1% in the prior-year quarter. Segment revenue increased to ₹322.3 crore from ₹231.2 crore, while EBIT rose to ₹23.2 crore, supported by improved realisations and operating performance. IOLCP is positioning its manufacturing platform for higher-value growth through forward integration into contract development and manufacturing organisation services and formulations. Management views this as a natural extension of existing process expertise, intended to broaden customer solutions, deepen relationships and improve long-term portfolio quality.
Over the past 52 weeks, IOL Chemicals & Pharmaceuticals Ltd has traded between a low of ₹67.14 and a high of ₹224.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
IOL Chemicals & Pharmaceuticals Ltd has a market capitalization of approximately 5,425.86. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
IOL Chemicals & Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 32.28 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 5,425.86 Cr, IOL Chemicals & Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
IOL Chemicals & Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of IOL Chemicals & Pharmaceuticals Ltd is 32.28. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
IOL Chemicals & Pharmaceuticals has announced October 30, 2026 as the date for its Q2 FY27 results. The company has scheduled an analyst and investor call for November 2, 2026 at 11:30 AM IST.
Revenue from operations was ₹756.3 crore in Q1 FY27, up 37.1% year-on-year from ₹551.7 crore in Q1 FY26.
For the quarter ended June 30, 2026, revenue from operations was ₹756.26 crore and profit for the period was ₹64.48 crore on a standalone basis.
The stock rose after China’s NMPA approved IOL’s Fenofibrate, allowing the company to export the Fenofibrate API to the Chinese market.
